Valera Pharmaceuticals, Inc., a pharmaceutical company, engages in the development, acquisition, and commercialization of products for the treatment of urological and endocrine conditions, diseases, and disorders in the United States. The company develops various hydrogel-based implants, which are designed to release therapeutic agents at a controlled rate for up to 12 months. It provides Vantas, a 12-month implant for the palliative treatment of advanced prostate cancer that delivers histrelin, a luteinizing hormone-releasing hormone agonist. Valera Pharmaceuticals also developed Supprelin-LA, a 12-month implant to deliver histrelin for the treatment of central precocious puberty. Its...